116 related articles for article (PubMed ID: 7561242)
21. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
22. The biological significance of soluble interleukin-2 receptors in solid tumors.
Lissoni P; Barni S; Rovelli F; Viviani S; Maestroni GJ; Conti A; Tancini G
Eur J Cancer; 1990 Jan; 26(1):33-6. PubMed ID: 2138475
[TBL] [Abstract][Full Text] [Related]
23. Soluble interleukin-2 receptor as a clinical parameter for nasopharyngeal carcinoma.
Hsu MM; Chen YJ; Chang YL; Ko JY; Sheen TS
Asian Pac J Allergy Immunol; 1995 Jun; 13(1):1-4. PubMed ID: 7488337
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
25. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.
Li H; Wu M; Wu Z; Liang J; Wang L; Yang X; Lin Z; Li J
Cancer Immunol Immunother; 2022 Jun; 71(6):1519-1530. PubMed ID: 34724091
[TBL] [Abstract][Full Text] [Related]
27. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
31. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract][Full Text] [Related]
32. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
33. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
[TBL] [Abstract][Full Text] [Related]
34. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
35. Soluble interleukin-2 receptor levels and immune activation in patients with schistosomiasis and carcinoma of the urinary bladder.
Raziuddin S; Shetty S; Ibrahim A
Scand J Immunol; 1992 Jun; 35(6):637-41. PubMed ID: 1604238
[TBL] [Abstract][Full Text] [Related]
36. Expression of interleukin-2 receptor alpha (IL-2R alpha) mRNA and protein in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Wells AF; Nicosia SV; Roberts WS; Cavanagh D; Djeu JY
Anticancer Res; 1994; 14(3A):761-72. PubMed ID: 8074478
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy.
Mayerhofer K; Bodner K; Bodner-Adler B; Schindl M; Kaider A; Hefler L; Zeillinger R; Leodolter S; Joura EA; Kainz C
Cancer; 2001 Jan; 91(2):388-93. PubMed ID: 11180086
[TBL] [Abstract][Full Text] [Related]
38. Soluble interleukin-2 receptors and CA 125 in ovarian cancer, a longitudinal and cross-sectional study.
Burch D; Metcalfe S; Gallagher G; al-Azzawi F; Wheeler T
Eur J Gynaecol Oncol; 1994; 15(5):352-8. PubMed ID: 7828604
[No Abstract] [Full Text] [Related]
39. Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated.
de Bruijn HW; ten Hoor KA; van der Zee AG
Tumour Biol; 1998; 19(3):160-6. PubMed ID: 9591042
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.
Lin YH; Wu CH; Fu HC; Chen YJ; Chen YY; Ou YC; Lin H
Cancer Biomark; 2020; 28(3):285-292. PubMed ID: 32390605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
